Business
Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
Vebreltinib is efficacious in both treatment naïve and previously treated patients with NSCLC with METex14 skipping, and regardless of co-occurring MET
About this update from Apollomics Inc.
[{"type":"text","content":"Vebreltinib is efficacious in both treatment naïve and previously treated patients with NSCLC with METex14 skipping, and regardless of co-occurring MET amplification\nFOSTER CITY, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today a poster presentation at the 2024 European Society for Medical Oncology (ESMO) Congress, taking place September 13-17, 2024 in Barcelona, Spain. “We are pleased to share the efficacy and safety data of vebreltinib showing it is efficacious in both treatment naïve and previously treated patients with non-small cell lung cancer (NSCLS) and confirmed METex14 mutation, with longer treatment follow-ups,” said Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics. “Interestingly, the analysis of efficacy by MET gene copy number (GCN) demonstrated that not only the majority of the patient population in the vebreltinib program does not have co-occurring MET amplification and therefore resembles the real-world patient population reported in registries, but also that vebreltinib is efficacious regardless of co-occurring METamp, achieving as high as 67% overall response rate in patients with MET GCN","length":2089,"tagName":"div"}]